STOCK TITAN

[SCHEDULE 13G/A] Avalo Therapeutics, Inc. Amended Passive Investment Disclosure

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Point72 Asset Management and related entities report beneficial ownership of 627,502 shares of Avalo Therapeutics common stock, representing 3.5% of the class as of December 31, 2025. The stake is held through an investment fund managed by Point72, with no shares owned directly by the reporting persons.

Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen each report shared voting and dispositive power over these shares and no sole voting or dispositive power. They certify the investment is not for the purpose of changing or influencing control of Avalo Therapeutics.

Positive

  • None.

Negative

  • None.

Insights

Point72 and Steven A. Cohen report a passive 3.5% stake in Avalo Therapeutics.

Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen jointly report beneficial ownership of 627,502 Avalo Therapeutics shares, or 3.5% of the common stock as of December 31, 2025. The shares are held in an investment fund managed by Point72.

The filing emphasizes that none of the reporting persons directly own the shares; instead, Point72 Asset Management has investment and voting power under an investment management agreement, Point72 Capital Advisors, Inc. is its general partner, and Mr. Cohen controls both entities. This structure is typical for large asset managers.

The certification states the position is not held to change or influence control of Avalo Therapeutics, aligning with a passive Schedule 13G filing. Future ownership updates, if any, would appear in subsequent beneficial ownership reports rather than through control-related filings.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Point72 Asset Management, L.P.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Point72 Capital Advisors, Inc.
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Steven A. Cohen
Signature:/s/ Jason M. Colombo
Name/Title:Jason M. Colombo, Authorized Person
Date:02/17/2026
Avalo Therapeutics Inc

NASDAQ:AVTX

AVTX Rankings

AVTX Latest News

AVTX Latest SEC Filings

AVTX Stock Data

263.99M
1.57M
Biotechnology
Pharmaceutical Preparations
Link
United States
WAYNE